DSM Biomedical has partnered with Cerapedics to create and manufacture the next generation of peptide-enhanced bone graft.

The partnerships allows for DSM’s regenerative materials capabilities to be used with Cerapedics’s proprietary synthetic small peptide (P-15) technology.

Designed for fast and predictable remodeling in bone graft substitute applications, DSM’s newest bioceramic platform is make of a carbonated apatite matrix. The partnership states that DSM will provide collagen carrier, final packaging and full support throughout the product development process.

“The partnership combines the industry leading expertise and capabilities in bioceramic materials of DSM with Cerapedics’ innovative growth factor, delivering a new product solution to improve people’s lives,” David Yonce, VP and global head of innovation at DSM Biomedical, said. “Together, from concept to commercialization, we are at the leading edge of advanced healing solutions.”

Cerapedics’s P-15 technology supports bone growth through cell attraction, attachment and activation. The company plans to work with DSM to develop and commercialize Cerapedics’s next generation of P-15 technology.

“Over the past year we have been focused on accelerating our commercialization efforts in the U.S. following the FDA Premarket Approval (PMA) of i-FACTOR Bone Graft, and we are excited to be partnered with DSM in delivering our next generation product to market,” said Glen Kashuba, CEO of Cerapedics.

“The next generation product we’re developing with DSM is showing tremendous potential, and will allow us to bring the bone forming potential of the P-15 technology into the lumbar spine,” Jeffrey G. Marx, president and COO of Cerapedics, said.

DSM and Cerapedics will be showcasing their technologies at the North American Spine Society 2017 in Orlando Oct. 25-28. DSM can be found at booth #556 and Cerepedics will be at booth #533.